Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Everolimus (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen; Toremifene
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Jan 2019.
- 31 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2019.
- 08 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.